Due to the limited studies on CTLA-4 inhibitor monotherapy for advanced HCC, its anti-tumor activity and safety cannot be accurately assessed at this time, and more studies are expected to follow to validate it further. The gene discussed is CTLA4; the disease is neoplasm.